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Abstract: Hypotensive effects of statins. A place for hydrogen sulfide in the puzzle?
Lipid lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors — statins 
— significantly diminish the risk of cardiovascular morbidity and mortality in patients with 
cardiovascular diseases. Moreover, some clinical trials results indicate that this group of drugs 
reduces blood pressure, especially in patients with hypertension. In the article pleiotropic effects 
of statins that might have influence on blood pressure are discussed. Recent data on the role of 
gaseous messenger hydrogen sulfide (H2S) in cardiovascular biology and kidney physiology are 
presented with the focus on the latest findings of atorvastatin increasing H2S tissue concentration 
in kidneys.
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INTRODUCTION
Lipid lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors — statins — are the most commonly administered drugs in the treat-
ment of lipid disorders worldwide [1]. Clinical trials results indicate that statins 
decrease all cause mortality and cardiovascular mortality, the incidence of car-
diovascular events — transient ischaemic attacks and stroke, acute coronary 
syndromes and coronary revascularization rates in patients after myocardial 
infarction and in groups of high cardiovascular risk [2, 3]. This beneficial im-
pact on the cardiovascular system results not only from statins’ lipid-lowering 
action but also from a wide variety of effects they exert on atherosclerotic plaques, 
endothelium and their antioxidant and anti-inflammatory properties [4]. Inter-
estingly, it has been lately also proclaimed that HMG-CoA reductase inhibi-
tors reduce blood pressure, especially in patients with hypertension [5, 6]. The 
mechanisms of this action are not clear. Different biological systems are pos-
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tulated to be involved. Here we discuss their possible role in light of the recent 
data on hydrogen sulfide — an important cardiovascular function and blood 
pressure regulator [7].
PLEIOTROPIC EFFECTS OF STATINS
HMG-CoA reductase is the rate controlling enzyme of the mevalonate pathway 
that produces cholesterol and other isoprenoids, so statins decrease choles-
terol synthesis but also isoprenoids generation, mainly farnesyl pyrophosphate 
and geranyl pyrophosphate. These compounds normally attach post-transla-
tionally to intracellular signaling proteins including nuclear lamins, guanosine 
triphosphates — Rho, Rac, Rap and Ras, G-proteins and enable proper sub-
cellular localization and trafficking of intracellular proteins. Since those modi-
fied proteins control diverse cellular function, statins exert additional effects 
 beyond lipid lowering and resulting from altered isoprenoids system. Further-
more,  numerous studies have shown that HMG-CoA reductase inhibitors have 
a broad array of anti-inflammatory, antiproliferative and immunomodulatory 
actions, described commonly as pleiotropic effects (Table 1) [1, 8].
T a b l e  1  —  T a b e l a  1
Pleiotropic effects of statins
Plejotropowe działanie statyn
↓ ET-1 ↓ LDL oxidation ↑ NO
↓ Il-6 ↓ histamine release by basophils ↑ CO
↓ VCAM-1 and ICAM-1 ↓ interferon gamma-induced MHC 
class II expression
↑ PPAR-α
↓ PDGF ↓ T-cell activation ↑ apoA-I expression
↓ NF-κB activation ↓ monocyte activation ↑ PI3K/Akt
↓ endothelial cell activation ↓ leukocyte-endothelial cell 
adhesion
↑ inhibition of leukocyte 
function antigen-1
↓ CRP ↓ proinflammatory cytokines 
(MCP-1, TNF-α)
↑ resistance to complement
↓ ROS ↓ PAI-1 ↑ t-PA
↓ factor XIII ↓ thrombin ↓ factor Va 
ET-1 — endothelin 1, Il-6 — interleukin 6, VCAM-1 — vascular cell adhesion molecule-1,  
ICAM-1 — intercellular cell adhesion molecule-1, PDGF — platelet-derived growth factor, NF-κB — nuclear 
factor kappa-light-chain-enhancer of activated B cells protein complex, CRP — C-reactive protein, 
ROS — reactive oxygen species, LDL — low density lipoproteins, MHC — major histocompatibility complex, 
MCP-1 — monocyte chemotactic protein-1, TNF-α — tumor necrosis factor α, PAI-1 — plasminogen activator 
inhibitor-1, NO — nitric oxide, CO — carbon monoxide, PPAR-α — peroxisome proliferator-activated receptor α, 
apoA-I — apolipoprotein A-I, PI3K/Akt — phosphatidylinositol-3-kinase/Akt pathway,  
tPA — tissue plasminogen activator
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MECHANISMS OF STATINS HYPOTENSIVE ACTION
One of the most important mechanisms postulated to contribute to blood 
pressure decrease elicited by statins is the improvement of endothelial fun-
ction [9, 10]. During statin therapy vasorelaxant mechanisms amended and 
arterial stiffness in long-term observations declined [11, 12]. Increased nitric 
oxide (NO) bioavailability was reported, while levels of oxidatively modified low-
density lipoprotein (ox-LDL) and endotelin-1 (ET-1) fell [13–15]. Vasocostrictive 
and pressory effects of angiotensin II and norepinephrine were reduced while 
susceptibility to vasorelaxant action of angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers and calcium channel blockers soared [16–18]. 
Moreover, in patients with hipercholesterolaemia rise in angiotensin II recep-
tors AT1 density was observed and statin therapy reversed this process, and 
a subsequent drop in aldosterone concentrations was noted [19, 20]. Among 
effects of HMG-CoA reductase inhibitors that can lead to fall in blood pressure 
an influence on autonomic nervous system should also be taken into account. 
Statins significantly reduced sympathetic activity, increased parasympathetic 
activity and improved baroreflex sensitivity [21–23].
EMERGING BIOLOGICAL CRUCIAL ROLE  
OF HYDROGEN SULFIDE
The cell and organ function in mammals is modulated by a variety of signal 
molecules including lipids, peptides, small and inorganic molecules with ions 
and amino acids, and numerous metabolism intermediates. Among these sig-
nal carriers a special place has a family of gaseous compounds with NO and 
carbon monoxide (CO) at the forefront. These so-called ‘gasotransmitters’ have 
been proven to play a crucial role in cardiovascular biology, blood pressure and 
flow regulation. NO i.a. stimulates guanylate cyclases and degradative  enzymes 
like phosphodiesterases. CO resembles this action but with much lower po-
tency [24, 25]. Studies from recent years have been revealing that a third ga-
seous molecule hydrogen sulfide (H2S) is deeply implicated in the regulation of 
many physiological and pathological processes including neurotransmission, 
insulin secretion, immune and inflammatory processes, gastric mucosal inte-
grity, intestinal motility, perception and vascular tone control [7, 26].
H2S is endogenously formed from L-cysteine in several enzymatic reactions, 
catalyzed by cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE) and 
3-mercaptopyruvate sulfurtransferase (3MST). CBS is mainly expressed in 
nervous system, liver and kidney, while CSE is mostly found in vascular and 
non-vascular smooth cells and in the liver. H2S is also formed in non-enzymatic 
pathways in many tissues and in erythrocytes. Intestinal flora is also a source 
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of the gas in the organism. H2S participates in the relaxation of vessels by 
opening of adenosine triphosphate (ATP)-sensitive potassium channels and 
increasing Cl-/HCO3- exchanger activity and metabolic inhibition (cytochrome 
c inhibition) in the vascular smooth muscle cells [27–30]. H2S interacts with 
carbon monoxide (CO) and nitric oxide (NO) systems in a complex manner in-
cluding affecting each other’s synthesis and biological responses within target 
tissues and organs. Moreover, all these three gases bind to haemoglobin and 
inhibit mitochondrial oxidative phosphorylation by impeding cytochrome c oxi-
dase [24].
HYDROGEN SULFIDE, BLOOD PRESSURE  
AND KIDNEY FUNCTION
The role of H2S in the regulation of blood pressure was explored by Yang and 
al. in the group of CSE lacking mice (CSE KO) [31]. The main observations 
showed 50–80% reduction of H2S tissue concentration in arteries, liver and 
kidney and 50% decrease of H2S serum level. As soon as seven weeks after 
birth the mice developed arterial hypertension with systolic blood pressure aro-
und 20 mm Hg higher than the control group. Infusion of H2S reduced blood 
pressure in healthy mice and CSE KO individuals, but the response in the 
latter was much more pronounced. In the other part of the experiment, when 
isolated mesenteric arteries were examined, arteries of CSE KO showed redu-
ced by 50–60% vasorelaxative effect of acetylcholine, what points that vasore-
laxation is influenced by H2S generated by endothelial CSE. These data prompt 
to consider H2S as a part of endothelium-derived relaxing factors (EDRFs). 
H2S shares other features of EDRFs with NO such as the acute regulation by 
vasorelaxative hormones through calmodulin and inositol-1,4,5-triphosphate 
(IP3)-dependent pathways [25].
In the kidney both CBS and CSE were identified to produce hydrogen 
sulfide. H2S has been recognized as a participant of the control of renal func-
tion which involves both vascular and tubular actions. In the study on rats 
of Xia et al. induction of endogenous H2S production with L-cysteine (L-Cys) 
infusion into renal artery increased glomerular filtration rate (GFR), urinary 
sodium and potassium excretion. The inhibitory effect of H2S on tubular rea-
bsorption has been shown to involve Na+/K+/2Cl- cotransporter (NKCC) and 
Na+/K+-ATPase (NKA). Exogenous H2S produced dose-related increases renal 
blood flow, GFR and urinary excretion [32]. H2S has been also identified to 
inhibit angiotensin-converting enzyme (ACE) by complexing with the zinc atom 
at its active site [33].
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STATINS AND HYDROGEN SULFIDE
Recently the influence of two doses of atorvastatin on H2S tissue concentra-
tion in different organs of mice was examined. The effect of the drug on brain, 
liver and heart did not exceed 10.6% of H2S tissue level. In the kidney lower 
dose of atorvastatin induced 9.7% rise in H2S concentration (control group: 
5.26 ± 0.09 μg/g, atorvastatin dose 5 mg/kg b.w./d group: 5.77  ±  0.11 μg/g, 
p = 0.0003); while higher dose increased H2S level by 42.2% (atorvastatin 
20 mg/kg b.w./d group: 7.48  ±  0.09 μg/g, p < 0.0001) [34]. This experiment 
outcome and previously discussed data show that endogenous H2S may have 
contribution to the effect of atorvastatin on blood pressure. Subgroup analyses 
of major clinical studies and meta-analyses of smaller trials indicate that statin 
therapy slows the decline of the glomerular filtration rate and reduce protei-
nuria in patients with chronic kidney disease. In researchers’ opinion statins 
have been appearing to protect the kidneys through complex unclear non-
cholesterol-mediated mechanisms apart from effects of lipid lowering [35, 36]. 
These observations encourage to explore the role of H2S in physiology and pa-
thology of kidney. 
Bogdan Wiliński1, Jerzy Wiliński2, eugeniusz somogyi3
DZIAŁANIE HIPOTENSYJNE STATYN. CZY JEST MIEJSCE DLA SIARKOWODORU 
W TEJ UKŁADANCE?
S t r e s z c z e n i e
Obniżające poziom cholesterolu we krwi statyny (inhibitory reduktazy 3-hydroksy-3-metylo- 
glutarylo-koenzymu A) zmniejszają ryzyko chorobowości i śmiertelności sercowo-naczyniowej 
u osób z chorobami układu krążenia. Wyniki niektórych badań wskazują ponadto, że ta grupa 
leków obniża ciśnienie tętnicze. W prezentowanym artykule dyskutowane są plejotropowe efekty 
działania statyn, które mogą mieć wpływ na ciśnienie tętnicze. Przedstawione są wyniki badań na 
temat roli siarkowodoru (H2S) w układzie sercowo-naczyniowym oraz fizjologii nerek z uwzględnie-
niem najnowszych eksperymentalnych danych wskazujących, że atorwastatyna zwiększa tkankowe 
stężenie H2S w nerkach.
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